Management of Bone Hardware Infections

Initial Treatment Approach

The Infectious Diseases Society of America recommends vancomycin IV (15-20 mg/kg/dose every 8-12 hours) as the primary parenteral antibiotic for MRSA osteomyelitis with hardware, with the addition of rifampin (600 mg daily or 300-450 mg twice daily) due to its excellent penetration into bone and biofilm 1, 2, 3
Surgical debridement and drainage of associated soft-tissue abscesses is the cornerstone of therapy and should be performed whenever feasible, as recommended by the Infectious Diseases Society of America 1, 2
A minimum 8-week course of therapy is recommended for MRSA osteomyelitis involving hardware, according to the Infectious Diseases Society of America 1, 3
Daptomycin 6 mg/kg/dose IV once daily is an effective alternative when vancomycin cannot be used, as suggested by the Infectious Diseases Society of America 1, 2
Linezolid 600 mg PO/IV twice daily can be used, but caution is advised for use beyond 2 weeks due to myelosuppression risk, as warned by the Infectious Diseases Society of America 2, 3

For gram-negative bacilli, a third- or fourth-generation cephalosporin (such as cefepime 2g IV every 8-12 hours) or a carbapenem is recommended by the Infectious Diseases Society of America 4, 5
For Pseudomonas aeruginosa, cefepime, meropenem, or doripenem is preferred, as recommended by the Infectious Diseases Society of America 4
In cases of suspected ESBL-producing organisms, carbapenems are the treatment of choice, according to the Infectious Diseases Society of America 5

With stable implants and short duration of symptoms (<3 weeks): initial parenteral therapy plus rifampin for 2 weeks is recommended by the Infectious Diseases Society of America 1
Followed by rifampin plus a companion oral drug (ciprofloxacin, levofloxacin, TMP-SMX, tetracycline, or clindamycin) for a total of 3 months for hips and 6 months for knees, as suggested by the Infectious Diseases Society of America 1
Device removal whenever feasible is strongly recommended by the Infectious Diseases Society of America 1

Obtain cultures before initiating antibiotics whenever possible, as recommended by the Infectious Diseases Society of America 4
Initiate empiric therapy while awaiting culture results: Vancomycin IV (15-20 mg/kg/dose every 8-12 hours) for suspected MRSA, and add cefepime or a carbapenem for suspected gram-negative infection, as recommended by the Infectious Diseases Society of America 1, 2, 4, 5
Perform surgical debridement as soon as feasible, as recommended by the Infectious Diseases Society of America 1, 2
Adjust antibiotics based on culture results, and consider switching to a beta-lactam for susceptible staphylococci, as suggested by the Infectious Diseases Society of America 1, 3, 4, 5

Vancomycin has shown failure rates of up to 35-46% in MRSA osteomyelitis, with concerns about poor bone penetration, as reported by the Infectious Diseases Society of America 1, 3
Rifampin should always be combined with another active agent to prevent emergence of resistance, and should be added only after clearance of bacteremia to prevent development of resistance, as recommended by the Infectious Diseases Society of America 1, 3
Linezolid should not be used for more than 2 weeks without close monitoring due to risk of myelosuppression, as warned by the Infectious Diseases Society of America 3

Surgical debridement is strongly recommended but not absolutely mandatory in all cases, depending on the extent of bone necrosis, presence of hardware, and clinical response to antibiotics, with outcomes significantly better with surgical intervention, as recommended by the Infectious Diseases Society of America 6
If extensive bone destruction, necrotic bone, or hardware is present, surgical debridement should be performed as soon as feasible, as this is the cornerstone of therapy and significantly improves cure rates, according to the Infectious Diseases Society of America 6
The 2012 IDSA diabetic foot infection guidelines acknowledge that clinicians can consider using either primarily surgical or primarily medical strategies for treating osteomyelitis in properly selected patients, including those with early osteomyelitis without extensive bone destruction, patients who are poor surgical candidates, or cases where adequate bone cultures can be obtained percutaneously, as stated by the Infectious Diseases Society of America 6
Obtain bone cultures during debridement to guide definitive antibiotic therapy, as wound cultures may not reflect bone pathogens, as recommended by the Infectious Diseases Society of America 6 and supported by Radiology 7 and 8

For vancomycin-intermediate resistant organisms, daptomycin-rifampin therapy is recommended, with daptomycin 6 mg/kg IV once daily PLUS rifampin 600 mg daily, as an alternative to vancomycin, according to the Infectious Diseases Society of America 6

If radical debridement removes all infected/necrotic tissue, 2-5 days of antibiotics post-operatively are recommended, as stated by the Infectious Diseases Society of America 6
If residual infected or necrotic bone remains, minimum 4-6 weeks of antibiotic therapy are recommended, according to the Infectious Diseases Society of America 6

Urgent surgical drainage of a psoas abscess (open or CT‑guided percutaneous) is required because medical therapy alone is insufficient. 9
Radical debridement of all infected and necrotic bone and soft tissue is essential; inadequate source control is the primary cause of treatment failure. 9

Vancomycin dosing: 15–20 mg/kg IV every 8–12 hours with target trough concentrations of 15–20 µg/mL for confirmed MRSA osteomyelitis. 10
Rifampin‑based combination therapy (added after surgical debridement and clearance of bacteremia) reduces recurrence risk by approximately 77% (adjusted hazard ratio 0.23). 11

Blood‑culture surveillance: Obtain repeat blood cultures 2–4 days after the initial positive set to confirm clearance of bacteremia before initiating rifampin. 11
Inflammatory markers: Measure ESR and CRP weekly; successful therapy is reflected by a consistent downward trend. 11
Imaging: Perform a repeat MRI 4–6 weeks after surgery to evaluate resolution of the psoas abscess and bone signal abnormalities. 12

Aggressive glycemic control is recommended because hyperglycemia impairs wound healing and immune function, increasing the risk of treatment failure and mortality. 12